drugset / Trial / NCT05415462

A Study of mRNA-1010 Seasonal Influenza Vaccine in Adults

NCT05415462

Phase 3 Completed 6102 enrolled ModernaTX, Inc.
RandomizedParallel-groupQuadruple-blindPrevention

Summary

The primary objectives of this study are to evaluate the humoral immunogenicity of mRNA-1010 relative to that of an active comparator against vaccine-matched influenza A and B strains at Day 29, and to evaluate the safety and reactogenicity of mRNA-1010.

Timeline

Start
2022-06-06
Primary completion
2023-09-04
Completion
2023-09-04

Drugs

EvaluationDrugModalityDoseRoute
Comparator Fluarix Tetra Vaccine Intramuscular
Subject Quadrivalent influenza vaccine Vaccine Intramuscular

Indications